Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial

Therapeutic Advances in Respiratory Disease

Volumn 12, Issue , 2018, Pages

  Płoszczuk, Anna ^a   Bosheva, Miroslava ^b   Spooner, Kay ^c   McIver, Tammy ^c   Dissanayake, Sanjeeva ^c  

^a Prywatna Praktyka Lekarska   (Poland)

^b MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^c Mundipharma Research Limited   (Germany)

Author keywords

asthma; children; combination therapy; fluticasone propionate; formoterol fumarate; ICS LABA

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE-FORMOTEROL; FORMOTEROL FUMARATE; GLUCOCORTICOID;

AREA UNDER THE CURVE; ARM FRACTURE; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; BRONCHITIS; CHILD; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; TREATMENT DURATION; VIRAL RHINITIS; AGE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG; METERED DOSE INHALER; PATHOPHYSIOLOGY; POLAND; PRESCHOOL CHILD; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGE FACTORS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FLUTICASONE; FLUTICASONE-SALMETEROL DRUG COMBINATION; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; METERED DOSE INHALERS; POLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 85054616692     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753466618777924     Document Type: Article

References (44)

1. Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention, 2016; http://ginasthma.org/
2. Ni Chroinin M, Lasserson TJ, Greenstone I. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009; 8: CD007949
3. Murphy K, Bender B., Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy 2009; 2: 63–72
4. GlaxoSmithKline Briefing Document. Benefit risk assessment of salmeterol for the treatment of asthma in adults and children, 2008; https://wayback.archive-it.org/7993/20170405035641/https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-04-GSK.pdf
5. Bodzenta-Lukaszyk A, Pulka G, Dymek A. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011; 105: 674–682
6. Bodzenta-Lukaszyk A, Dymek A, McAulay K. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011; 11: 28
7. Nathan RA, D’Urzo A, Blazhko V. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med 2012; 12: 67
8. Bodzenta-Lukaszyk A, Buhl R, Balint B. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma 2012; 49: 1060–1070
9. Aalbers R, Brusselle G, McIver T. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther 2012; 29: 958–969
10. Corren J, Mansfield LE, Pertseva T. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med 2013; 107: 180–195
11. Kaiser K, Pertseva T., Long-term safety and efficacy of fluticasone propionate/formoterol fumarate combination therapy in patients with asthma. Prim Care Respir J 2013; 22: A1–A18
12. Bodzenta-Lukaszyk A, Van Noord J, Schroder-Babo W. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial. Curr Med Res Opin 2013; 29: 579–588
13. Mansur AH, Kaiser K., Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv 2013; 26: 190–199
14. Papi A, Mansur AH, Pertseva T. Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. J Aerosol Med Pulm Drug Deliv 2016; 29: 346–361
15. Emeryk A, Klink R, McIver T. A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma. Ther Adv Respir Dis 2016; 10: 324–337
16. Reddel HK, Taylor R, Bateman ED. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99
17. Miller MR, Hankinson J, Brusasco V. Series ATS/ERS task force: standardisation of lung function testing’ standardisation of spirometry. Eur Respir J 2005; 26: 319–338
18. Fuhlbrigge AL, Kitch BT, Paltiel AD. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107: 61–67
19. Fuhlbrigge AL, Weiss ST, Kuntz KM.; CAMP Research Group. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics 2006; 118: e347–e355
20. Covar RA, Szefler SJ, Zeiger RS. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol 2008; 122: 741–747
21. European Medicines Agency/399193/2012. Flutiform assessment report pursuant to Article 29(4) of Directive 2001/83/EC, as amended, http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flutiform_29/WC500134240.pdf
22. Malone R, La Force C, Nimmagadda S. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005; 95: 66–71. And unpublished data in SAS30031
23. Tal A, Simon G, Vermeulen JH. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonol 2002; 34: 342–350
24. 1 spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy. Eur Respir J 2013; 42: P4131
25. Pohunek P, Kuna P, Jorup C. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol 2006; 17: 548–465
26. Morice AH, Peterson S, Beckman O. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulm Pharmacol Ther 2008; 21: 152–159
27. Malone R, La Force C, Nimmagadda S. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005; 95: 66–71
28. Tal A, Simon G, Vermeulen JH. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34: 342–350
29. Santanello NC., Pediatric asthma assessment: validation of 2 symptom diaries. J Allergy Clin Immunol 2001; 107: S465–S472
30. Yawn BP, Brennemen SK, Allen-Ramey FC. Assessment of asthma severity and asthma control in children. Pediatrics 2006; 118: 322–329
31. Kuehni CE, Frey U., Age-related differences in perceived asthma control in childhood: guidelines and reality. Eur Respir J 2002; 20: 880–889
32. Santanello NC, Davies G, Galant SP. Validation of an asthma symptom diary for interventional studies. Arch Dis Child 1999; 80: 414–420
33. Zhang L, Axelsson I, Chung M. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011; 127: 129–138
34. Verona E, Petrov D, Cserhati E. Fluticasone propionate in asthma: a long term dose comparison study. Arch Dis Child 2003; 88: 503–509
35. Adams NP, Bestall JC, Jones P. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; CD003534
36. Chauhan BF, Ben Salah R, Ducharme FM., Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Database Syst Rev 2013; 10: CD009585
37. 2-agonists in asthma. Drug Safety 2004; 27: 234–270
38. Bisgaard H., Effect of long-acting beta 2 agonists on exacerbations rates of asthma in children. Pediatr Pulmonol 2003; 36: 391–398
39. Stempel DA, Szefler SJ, Pedersen S. Safety of adding salmeterol to fluticasone propionate in children with asthma. New Engl J Med 2016; 375: 840–849
40. Dissanayake SB., Safety of β2-agonists in asthma: linking mechanisms, meta-analyses and regulatory practice. AAPS J 2015; 17: 754–757
41. Kelly HW, Sternberg AL, Lescher R. Effect of inhaled glucocorticoids in childhood on adult height. New Engl J Med 2012; 367: 904–912
42. Loke YK, Blanco P, Thavarajah M. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One 2015; 10: e0133428
43. Pruteanu AI, Chauhan BF, Zhang L. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev 2014; 17: CD009878
44. Lemanske RF, Mauger DT, Sorkness CA. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. New Engl J Med 2010; 362: 975–985